МЕДИКЛОН

ООО "Медиклон"

127276 Москва, Ботаническая ул., 35, т\ф +7495 231-2272 +7499 502-1214

ПАСПОРТ-СЕРТИФИКАТ ПРОИЗВОДИТЕЛЯ
на «Набор реагентов для определения групп крови человека систем АВО, Резус и Kell» по ТУ-9398-101-51203590-2009
(ЦОЛИКЛОНЫ Анти-А, Анти-В и Анти-АВ)
Регистрационное удостоверение № ФСР 2009/06043 от 05 ноября 2009 г

Наименование: Цоликлон Анти-В во флаконах по 10 мл с синими крышками

Серия: 095810 **Единица:** 100 мл

Изготовлен: 21.10.2019 **Количество единиц** 40

Годен до: 21.10.2021 **Объем серии:** 10000 мл.

Паспорт: В095810 от 21.10.2019

Наименование показателя	Норма по ТУ	Результаты испытаний
1. Внешний вид 1.1 Цоликлон анти-А 1.2 Цоликлон анти-В 1.3 Цоликлон анти-АВ	Прозрачная жидкость красного цвета. Прозрачная жидкость синего цвета. Прозрачная бесцветная жидкость.	Соответствует
2. Серологические свойства 2.1 Специфичность	Цоликлон анти-А не должен давать агглютинации с эритроцитами групп В(III) и О(I) Цоликлон анти-В не должен давать агглютинации с эритроцитами групп А(III) и О(I) Цоликлон анти-АВ не должен давать агглютинации с эритроцитами группы О(I)	Соответствует Соответствует Соответствует
2.1 Гемагглютинирующая способность	Агглютинация на плоскости эритроцитов А1 и В с соответствующими Цоликлонами должна появиться не позднее 10 сек. после смешивания	Соответствует 10 секунд
2.3 Титр	Титр Цоликлона анти-А в реакции агглютинации на плоскости с эритроцитами группы А(II) 1:32 - 1:64 Титр Цоликлона анти-В в реакции агглютинации на плоскости с эритроцитами группы В(III) 1 : 64	Соответствует 1:32 - 1: 64 Соответствует 1:64
	Титр Цоликлона анти-АВ в реакции агглютина-ции на плоскости с эритроцитами групп А(II) 1:32 - 1: 64 и В(III) 1 : 64	Соответствует 1:32 - 1: 64

Цоликлон соответствует требованиям ТУ - 9398-101-51203590-2009

Заведующая ОТК ООО «Медиклон» М.С. Орлова

МЕДИКЛОН

ООО "Медиклон"

127276 Москва, Ботаническая ул., 35, т\ф +7495 231-2272 +7499 502-1214

ПАСПОРТ-СЕРТИФИКАТ ПРОИЗВОДИТЕЛЯ
на «Набор реагентов для определения групп крови человека систем АВО, Резус и Kell» по ТУ-9398-101-51203590-2009
(ЦОЛИКЛОНЫ Анти-А, Анти-В и Анти-АВ)
Регистрационное удостоверение № ФСР 2009/06043 от 05 ноября 2009 г

Наименование: Цоликлон Анти-А во флаконах по 10 мл с красными крышками

Серия: 096111 **Единица:** 100 мл

Изготовлен: 05.11.2019 **Количество единиц** 40

Годен до: 05.11.2021 **Объем серии:** 10000 мл.

Паспорт: А096111 от 05.11.2019

Наименование показателя	Норма по ТУ	Результаты испытаний
1. Внешний вид 1.1 Цоликлон анти-А 1.2 Цоликлон анти-В 1.3 Цоликлон анти-АВ	Прозрачная жидкость красного цвета. Прозрачная жидкость синего цвета. Прозрачная бесцветная жидкость.	Соответствует
2. Серологические свойства 2.1 Специфичность	Цоликлон анти-А не должен давать агглютинации с эритроцитами групп В(III) и О(I) Цоликлон анти-В не должен давать агглютинации с эритроцитами групп А(III) и О(I) Цоликлон анти-АВ не должен давать агглютинации с эритроцитами группы О(I)	Соответствует Соответствует Соответствует
2.1 Гемагглютинирующая способность	Агглютинация на плоскости эритроцитов А1 и В с соответствующими Цоликлонами должна появиться не позднее 10 сек. после смешивания	Соответствует 10 секунд
2.3 Титр	Титр Цоликлона анти-А в реакции агглютинации на плоскости с эритроцитами группы А(II) 1:32 - 1:64 Титр Цоликлона анти-В в реакции агглютинации на плоскости с эритроцитами группы В(III) 1 : 64	Соответствует 1:32 - 1: 64 Соответствует 1:64
	Титр Цоликлона анти-АВ в реакции агглютина-ции на плоскости с эритроцитами групп А(II) 1:32 - 1: 64 и В(III) 1 : 64	Соответствует 1:32 - 1: 64

Цоликлон соответствует требованиям ТУ - 9398-101-51203590-2009

Заведующая ОТК ООО «Медиклон» М.С. Орлова

МЕДИКЛОН

ООО "Медиклон"

127276 Москва, Ботаническая ул., 35, т\ф (495) 231-2272 (499) 502-1214

ПАСПОРТ-СЕРТИФИКАТ ПРОИЗВОДИТЕЛЯ
на «Набор реагентов для определения групп крови человека систем АВО, Резус и Kell» по ТУ-9398-101-51203590-2009
(ЦОЛИКЛОН Анти-D Супер)
Регистрационное удостоверение № ФСР 2009/06043 от 05 ноября 2009 г

Наименование: Цоликлон Анти-D Супер во флаконах по 10 мл с зелеными крышками

Серия: 292711 **Единица:** 100 мл

Изготовлен: 05.11.2019 **Количество единиц** 40

Годен до: 05.11.2021 **Объем серии:** 10000 мл.

Паспорт: Дс292711 от 05.11.2019

Наименование показателя	Характеристика нормы по ТУ	Результаты испытаний
1. Внешний вид	Прозрачная жидкость светло-бежевого цвета	Соответствует
2. Серологические свойства		
2.1 Специфичность	Цоликлон Анти-D Супер не должен агглютинировать D(–) эритроциты.	Соответствует
2.2 Гемагглютинирующая способность	Четкая реакция агглютинации должна наступать в течение 30 сек. после смешивания реагента с D(+) эритроцитами	Соответствует 30 сек.
2.3 Титр	Титр Цоликлона Анти-D Супер в реакции агглютинации на плоскости с D(+) эритроцитами 1:32 Титр Цоликлона Анти-D Супер в реакции прямой агглютинации с D(+) эритроцитами в микропланшете не ниже 1:256	Соответствует 1:32 1:256

Цоликлон соответствует требованиям ТУ – 9398-101-51203590-2009

Заведующая ОТК ООО «Медиклон» М.С.Орлова

МЕДИКЛОН

ООО "Медиклон"

127276 Москва, Ботаническая ул., 35, т\ф +7495-231-2272 +7499-502-1214

ПАСПОРТ-СЕРТИФИКАТ ПРОИЗВОДИТЕЛЯ
на «Набор реагентов для определения групп крови человека систем АВО, Резус и Kell» по ТУ-9398-101-51203590-2009
(ЦОЛИКЛОНЫ Анти-А, Анти-В и Анти-АВ)
Регистрационное удостоверение № ФСР 2009/06043 от 05 ноября 2009 г

Наименование: Цоликлон Анти-АВ

Серия: 098611 **Единица:** 100 мл

Изготовлен: 05.11.2019 **Количество единиц** 10

Годен до: 05.11.2021 **Объем серии:** 10000 мл.

Паспорт: АВ098611 от 05.11.2019

Наименование показателя	Норма по ТУ	Результаты испытаний
1. Внешний вид 1.1 Цоликлон анти-А 1.2 Цоликлон анти-В 1.3 Цоликлон анти-АВ	Прозрачная жидкость красного цвета. Прозрачная жидкость синего цвета. Прозрачная бесцветная жидкость.	Соответствует
2. Серологические свойства 2.1 Специфичность	Цоликлон анти-А не должен давать агглютинации с эритроцитами групп В(III) и О(I) Цоликлон анти-В не должен давать агглютинации с эритроцитами групп А(II) и О(I) Цоликлон анти-АВ не должен давать агглютинации с эритроцитами группы О(I)	Соответствует Соответствует Соответствует
2.1 Гемагглютинирующая способность	Агглютинация на плоскости эритроцитов А1 и В с соответствующими Цоликлонами должна появиться не позднее 10 сек. после смешивания	Соответствует 10 секунд
2.3 Титр	Титр Цоликлона анти-А в реакции агглютинации на плоскости с эритроцитами группы А(II) 1:32 - 1:64 Титр Цоликлона анти-В в реакции агглютинации на плоскости с эритроцитами группы В(III) 1 : 64 Титр Цоликлона анти-АВ в реакции агглютина-ции на плоскости с эритроцитами групп А(II) 1:32 - 1: 64 и В(III) 1 : 64	Соответствует 1:32 - 1: 64 Соответствует 1:64 Соответствует 1:32 - 1: 64

Цоликлон соответствует требованиям ТУ – 9398-101-51203590-2009

Заведующая ОТК ООО «Медиклон» М.С. Орлова

МЕДИКЛОН

ООО "Медиклон"

127276 Москва, Ботаническая ул., 35 . т\ф (495) 231-2272 (499) 502-1214

ПАСПОРТ-СЕРТИФИКАТ ПРОИЗВОДИТЕЛЯ
на «Набор реагентов для определения групп крови человека систем АВО, Резус и Kell» по ТУ-9398-101-51203590-2009
(ЦОЛИКЛОН Анти-Kell Супер)
Регистрационное удостоверение № ФСР 2009/06043 от 05 ноября 2009 г

Наименование: Цоликлон Анти-Kell Супер
Серия: 196410 **Единица:** 100 мл
Изготовлен: 21.10.2019 **Количество единиц** 10
Годен до: 21.10.2021 **Объем серии:** 10000 мл.
Паспорт: К196410 от 21.10.2019

Наименование показателя	Характеристика нормы по ТУ	Результаты испытаний
1.Внешний вид	Прозрачная желтоватая или розоватая жидкость	Соответствует
2. Серологические свойства		
2.1 Специфичность	Цоликлон Анти-Kell супер не должен агглютинировать эритроциты К(-)	Соответствует
2.2 Гематглютинирующая способность	Четкая реакция агглютинации на плоскости должна наступать в течение 30 сек. после смешивания	Соответствует
2.2 Активность	Титр Цоликлона Анти-Kell Супер в реакции прямой агглютинации в микропланте не ниже 1:16	Соответствует 1:16

Цоликлон соответствует требованиям ТУ – 9398-101-51203590-2009
Заведующая ОТК ООО «Медиклон» М.С.Орлова

МЕДИКЛОН

ООО "Медиклон"

127276 Москва, Ботаническая ул., 35 ; т\ф (495) 231-2272 (499) 502-1214

ПАСПОРТ-СЕРТИФИКАТ ПРОИЗВОДИТЕЛЯ
на «Набор реагентов для определения групп крови человека систем АВО, Резус и Kell» по ТУ-9398-101-51203590-2009
(ЦОЛИКЛОН Анти-D (IgG))
Регистрационное удостоверение № ФСР 2009/06043 от 05 ноября 2009 г

Наименование: Цоликлон Анти-D(IgG)
Серия: 292110 **Единица:** 100 мл
Изготовлен: 28.10.2019 **Количество единиц** 10
Годен до: 28.10.2021 **Объем серии:** 10000 мл.
Паспорт: Дж292110 от 28.10.2019

Наименование показателя	Характеристика нормы	Результаты испытаний
1. Внешний вид	Прозрачная жидкость светло-бежевого цвета	Соответствует
2. Серологические свойства		
2.1 Специфичность	Цоликлон Анти-D не должен агглютинировать D(-) эритроциты.	Соответствует
2.2 Гематглютинирующая способность	Агглютинация эритроцитов D+ с Цоликлоном в пробирочном тесте с желатином должна появляться не позднее 15 мин.	Соответствует
2.3 Титр	Титр Цоликлона анти-D в пробирочном тесте с желатином 1:128. Титр Цоликлона в непрямом антиглобулиновом тесте : 1:512	Соответствует

Цоликлон соответствует требованиям ТУ – 9398-101-51203590-2009

Заведующая ОТК ООО «Медиклон» М.С.Орлова

LORNE LABORATORIES

Date: 21-01-20

To Whom It May Concern

Letter of Authorisation

This is to confirm that GBG-MLD SRL of str. Tighina 65, of 607, MN-2001, Chisinau, Republic of Moldova is an authorised distributor for Lorne Laboratories Limited in Moldova.

GBG-MLD SRL is authorised to present proposals, offer quotations, accept orders and participate in tender number 18/0003 for the National Blood Transfusion Center for products on behalf of Lorne Laboratories Limited. This authorisation is valid until 31.12.2021.

The undersigned herewith states that the above is true and correct.

LORNE LABORATORIES LIMITED
Unit 1 Cutbush Park Industrial Estate
Danehill
Lower Earley
Berkshire RG6 4UT
United Kingdom

Ian John
Managing Director

And duly authorised to sign this Authorisation on behalf of Lorne Laboratories Limited

Lorne Laboratories Limited
Unit 1 Cutbush Park Industrial Estate
Danehill, Lower Earley
Berkshire RG6 4UT United Kingdom

Tel: +44 (0) 118 921 2264
Fax: +44 (0) 118 986 4518
Email: info@lornelabs.com
www.lornelabs.com

CERTIFICATE OF REGISTRATION

Lorne Laboratories Ltd

Unit 1 Cutbush Park Industrial Estate
Danehill
Lower Earley
Berkshire RG6 4UT UNITED KINGDOM

UL LLC® (UL) issues this certificate to the Firm named above, after assessing the Firm's quality system and finding it in compliance with:

ISO 13485:2016

EN ISO 13485:2016

The manufacture of in vitro diagnostic blood grouping reagents. The purchase for resale of in vitro diagnostic serology test kit.

Authorized by

Michael J. Windler, P.E.
Manager of Global Regulatory Service
Distinguished Member of the Technical Staff
UL Life and Health Sciences
UL LLC

Check Certificate Status: here

4426

File Number	A12241	Cycle Start Date	June 26, 2018
Certificate	1458.180626	Effective Date	June 26, 2018
Initial Issue	June 26, 2018	Expiry Date	May 22, 2020

This quality system registration is included in UL's Directory of Registered Firms and applies to the provision of goods and/or services as specified in the scope of registration from the address(es) shown above. By issuance of this certificate the firm represents that it will maintain its registration in accordance with the applicable requirements. This certificate is not transferable and remains the property of UL LLC.

UL LLC
333 Pfingsten Road
Northbrook, IL 60062-2096
USA

CISQ is a member of

IQNet
THE INTERNATIONAL CERTIFICATION NETWORK
www.iqnet-certification.com

IQNet, the association of the world's first class certification bodies, is the largest provider of management System Certification in the world. IQNet is composed of more than 30 bodies and counts over 150 subsidiaries all over the globe.

ICIM

CERTIFICATO n. / *CERTIFICATE No.* **4265/4/C**

SI CERTIFICA CHE IL SISTEMA DI GESTIONE PER LA QUALITÀ DI
WE HEREBY CERTIFY THAT THE QUALITY MANAGEMENT SYSTEM OPERATED BY

KIMA S.R.L.

UNITÀ OPERATIVE / *OPERATIVE UNITS*

Via Leonardo Da Vinci, 22 - Zona Industriale Tognana - 35028 Piove di Sacco (PD)
Italia

È CONFORME ALLA NORMA / *IS IN COMPLIANCE WITH THE STANDARD*

UNI CEI EN ISO 13485:2016

Sistema di Gestione per la Qualità / *Quality Management System*

PER LE SEGUENTI ATTIVITÀ / *FOR THE FOLLOWING ACTIVITIES*

EA: 29

Commercializzazione di prodotti del Gruppo: kit diagnostici, terreni di coltura per microbiologia, articoli in plastica per laboratorio analisi, provette con vuoto predeterminato e aghi sterili.

Trading of the products of the Group: diagnostic kits, culture media for microbiology, plastic disposable labware, test tubes with predetermined vacuum and sterile needles.

Riferirsi alla documentazione del Sistema di Gestione per la Qualità aziendale per l'applicabilità dei requisiti della norma di riferimento.
Refer to the documentation of the Quality Management System for details of application to reference standard requirements.

Per informazioni puntuali e aggiornate circa eventuali variazioni intervenute nello stato della certificazione di cui al presente certificato, si prega di contattare il n° telefonico +39 02 725341 o indirizzo e-mail info@icim.it.
For timely and updated information about any changes in the certification status referred to in this certificate, please contact the number +39 02 725341 or email address info@icim.it.

Data emissione	Emissione corrente	Data di scadenza
First issue	*Current issue*	*Expiring date*
18/01/2007	18/01/2019	17/01/2022

ICIM S.p.A.
Piazza Don Enrico Mapelli, 75 – 20099 Sesto San Giovanni (MI)
www.icim.it

ACCREDIA
L'ENTE ITALIANO DI ACCREDITAMENTO

SGQ N° 004 A

Membro degli Accordi di Mutuo Riconoscimento EA, IAF e ILAC
Signatory of EA, IAF and ILAC Mutual Recognition Agreements

FEDERAZIONE CISQ
www.cisq.com

CISQ è la Federazione Italiana di Organismi di Certificazione dei sistemi di gestione aziendale.
CISQ is the Italian Federation of management system Certification Bodies.

0860CM_02_IT

THE INTERNATIONAL CERTIFICATION NETWORK

CERTIFICATE

CISQ/ICIM SPA has issued an IQNet recognized certificate that the organization:

KIMA S.r.l.

Via Leonardo Da Vinci, 22 - Zona Industriale Tognana - I-35028 Piove di Sacco (PD)

has implemented and maintains a

Quality Management System

for the following scope:

Trading of the products of the Group: diagnostic kits, culture media for microbiology, plastic disposable labware, test tubes with predetermined vacuum and sterile needles.

which fulfils the requirements of the following standard:

ISO 13485:2016

Issued on:	**2019-01-18**
First issued on:	**2007-01-18**
Expires on:	**2022-01-17**

This attestation is directly linked to the IQNet Partner's original certificate and shall not be used as a stand-alone document.

Registration Number: IT-70247

Alex Stoichitoiu
President of IQNET

Ing. Claudio Provetti
President of CISQ

IQNet Partners*:
AENOR *Spain* AFNOR Certification *France* APCER *Portugal* CCC *Cyprus* CISQ *Italy*
CQC *China* CQM *China* CQS *Czech Republic* Cro Cert *Croatia* DQS Holding GmbH *Germany* FCAV *Brazil*
FONDONORMA *Venezuela* ICONTEC *Colombia* Inspecta Sertifiointi Oy *Finland* INTECO *Costa Rica*
IRAM *Argentina* JQA *Japan* KFQ *Korea* MIRTEC *Greece* MSZT *Hungary* Nemko AS *Norway* NSAI *Ireland*
NYCE-SIGE *México* PCBC *Poland* Quality Austria *Austria* RR *Russia* SII *Israel* SIQ *Slovenia*
SIRIM QAS International *Malaysia* SQS *Switzerland* SRAC *Romania* TEST St Petersburg *Russia* TSE Turkey YUQS *Serbia*
IQNet is represented in the USA by: AFNOR Certification, CISQ, DQS Holding GmbH and NSAI Inc.

* The list of IQNet partners is valid at the time of issue of this certificate. Updated information is available under www.iqnet-certification.com

0774CM_02_EN

Anticoagulanti - *Blood collection tubes*

SODIO CITRATO - *SODIUM CITRATE*

18610
NON STERILE

0,25 ml di sodio citrato in provetta in polipropilene.

0,25 ml of sodium citrate in polypropylene test tube.

Ø 12x56 mm.

18613
NON STERILE

0,25 ml di sodio citrato in provetta polipropilene.

0,25 ml of sodium citrate in polypropylene test tube.

Ø 16x58 mm.

18614
NON STERILE

0,25 ml di sodio citrato in provetta pollpropilene.

0,25 ml of sodium citrate in polypropylene test tube.

Ø 12x86 mm.



18608
NON STERILE

0,3 ml di sodio citrato in provetta polipropilene. Graduata a 3 ml.

0,3 ml of sodium citrate in polypropylene test tube. Graduated to 3 ml.

Ø 13x75 mm.

SODIO CITRATO - *SODIUM CITRATE*

18688
NON STERILE

0,3 ml di sodio citrato in provetta in polipropilene. Graduata a 3 ml.

0,3 ml of sodium citrate in polypropylene test tube. Graduated to 3 ml.

Ø 13x75 mm.

18561
NON STERILE

0,5 ml di sodio citrato in provetta in polipropilene.

0,5 ml of sodium citrate in polypropylene test tube.

Ø 16x58 mm.

18562
NON STERILE

0,5 ml di sodio citrato in provetta in polipropilene.

0,5 ml of sodium citrate in polypropylene test tube.

Ø 12x86 mm.

18564
NON STERILE

0,5 ml di sodio citrato in provetta polipropilene.

0,5 ml of sodium citrate in polypropylene test tube.

Ø 16x100 mm.

Provette monouso

Disposable test tubes

18016
NON STERILE

Vol. 5 ml.
Ø 12x86 mm.

Provetta cilindrica in polipropilene.
Opaca.
Graduata a 2,5-5 ml.

Polypropylene cylindrical test tube.
Translucid.
Graduated to 2,5-5 ml.

18018
NON STERILE

Vol. 5 ml.
Ø 12x86 mm.

Provetta cilindrica in polipropilene.
Con etichetta. Opaca.
Graduata a 2,5-5 ml.

Polypropylene cylindrical test tube.
With label. Translucid.
Graduated to 2,5-5 ml.

18020
NON STERILE

Vol. 5 ml.
Ø 12x86 mm.

Provetta cilindrica in polistirolo.
Trasparente.
Graduata a 2,5-5 ml.

Polystyrene cylindrical test tube.
Transparent.
Graduated to 2,5-5 ml.

18021
NON STERILE

Vol. 5 ml.
Ø 12x86 mm.

Provetta cilindrica in polistirolo.
Con etichetta. Trasparente.
Graduata a 2,5-5 ml.

Polystyrene cylindrical test tube.
With label.
Transparent. Graduated to 2,5-5 ml.

18012
NON STERILE

Vol. 10 ml.
Ø 16x100 mm.

Provetta conica in polipropilene.
Opaca.
Graduata a 0,5-1-2,5-5-10 ml.

Polypropylene conical test tube.
Translucid.
Graduated to 0,5-1-2,5-5-10 ml.

18014
NON STERILE

Vol. 10 ml.
Ø 16x100 mm.

Provetta conica in polipropilene.
Con etichetta. Opaca.
Graduata a 0,5-1-2,5-5-10 ml.

Polypropylene conical test tube.
With label. Translucid.
Graduated to 0,5-1-2,5-5-10 ml.

18304
NON STERILE

Vol. 10 ml.
Ø 16x100 mm.

Provetta conica in polistirolo.
Trasparente.
Graduata a 0,5-1-2,5-5-10 ml.

Polystyrene conical test tube.
Transparent.
Graduated to 0,5-1-2,5-5-10 ml.

18306
NON STERILE

Vol. 10 ml.
Ø 16x100 mm.

Provetta conica in polistirolo.
Con etichetta. Trasparente.
Graduata a 0,5-1-2,5-5-10 ml.

Polystyrene conical test tube.
With label. Transparent.
Graduated to 0,5-1-2,5-5-10 ml.

LORNE
LABORATORIES

EC DECLARATION OF CONFORMITY

Lorne Laboratories Ltd declares that the following in vitro diagnostic reagent:

Product name	Catalogue number
ASO Latex kit	031100A

has been classified as non List A, non List B (Directive 98/79/EC, Annex II) and complies with the essential requirements and provisions of Directive 98/79/EC of the European Parliament and of the Council (also SI 2002 No.618 which transposes the requirements of Directive 98/79/EC).

and is in conformity with the national standards transposing harmonised standards:

- BS EN 980:2008
- BS EN ISO 13485:2012
- BS EN 13612:2002
- BS EN 13640:2002
- BS EN 13641:2002
- BS EN ISO 14971:2012
- BS EN ISO 18113, parts 1&2

The conformity assessment procedure performed was in accordance with Annex III of Directive 98/79/EC.

This declaration of conformity is issued under the sole responsibility of Lorne Laboratories Ltd and is valid from 13 April 2016.

Eddy Velthuis
Technical Director

File No A12241;
ISO 13485:2003; ISO 9001:2008

Lorne Laboratories Limited
Unit 1 Cutbush Park Industrial Estate
Danehill, Lower Earley
Berkshire RG6 4UT United Kingdom

Tel: +44 (0) 118 921 2264
Fax: +44 (0) 118 986 4518
Email: info@lornelabs.com
www.lornelabs.com

LORNE LABORATORIES

EC DECLARATION OF CONFORMITY

Lorne Laboratories Ltd declares that the following in vitro diagnostic reagent:

Product name	Catalogue number
RF Latex kit	830100A

has been classified as non List A, non List B (Directive 98/79/EC, Annex II) and complies with the essential requirements and provisions of Directive 98/79/EC of the European Parliament and of the Council (also SI 2002 No.618 which transposes the requirements of Directive 98/79/EC).

and is in conformity with the national standards transposing harmonised standards:

- BS EN 980:2008
- BS EN ISO 13485:2012
- BS EN 13612:2002
- BS EN 13640:2002
- BS EN 13641:2002
- BS EN ISO 14971:2012
- BS EN ISO 18113, parts 1&2

The conformity assessment procedure performed was in accordance with Annex III of Directive 98/79/EC.

This declaration of conformity is issued under the sole responsibility of Lorne Laboratories Ltd and is valid from 13 April 2016.

Eddy Velthuis
Technical Director

Lorne Laboratories Limited
Unit 1 Cutbush Park Industrial Estate
Danehill, Lower Earley
Berkshire RG6 4UT United Kingdom

Tel: +44 (0) 118 921 2264
Fax: +44 (0) 118 986 4518
Email: info@lornelabs.com
www.lornelabs.com

LORNE LABORATORIES

EC DECLARATION OF CONFORMITY

Lorne Laboratories Ltd declares that the following in vitro diagnostic reagent:

Product name	Catalogue number
CRP Latex kit	850100A

has been classified as non List A, non List B (Directive 98/79/EC, Annex II) and complies with the essential requirements and provisions of Directive 98/79/EC of the European Parliament and of the Council (also SI 2002 No.618 which transposes the requirements of Directive 98/79/EC).

and is in conformity with the national standards transposing harmonised standards:

- BS EN 980:2008
- BS EN ISO 13485:2012
- BS EN 13612:2002
- BS EN 13640:2002
- BS EN 13641:2002
- BS EN ISO 14971:2012
- BS EN ISO 18113, parts 1&2

The conformity assessment procedure performed was in accordance with Annex III of Directive 98/79/EC.

This declaration of conformity is issued under the sole responsibility of Lorne Laboratories Ltd and is valid from 13 April 2016.

Eddy Velthuis
Technical Director

Lorne Laboratories Limited
Unit 1 Cutbush Park Industrial Estate
Danehill, Lower Earley
Berkshire RG6 4UT United Kingdom

Tel: +44 (0) 118 921 2264
Fax: +44 (0) 118 986 4518
Email: info@lornelabs.com
www.lornelabs.com

Declaration of Conformity

HL-7-0163DC DOI 2015/08 (9)

In Application of the Council Directive 98/79/EC on the approximation of the laws of the Member States relating to *In Vitro* Diagnostic Medical Devices & CE marking.

Declaration of conformance to applicable sections of Annex I - Essential Requirements and Annex III (EC Declaration of Conformity) imposed by sections 2 to 5. The below listed products are not classified under Annex II Lists A or B. Access to the appropriate technical files will be made available to the appropriate body in the event this is required.

Product Code	Description	GMDN Classification Code
5265	Thromboplastin LI	55983
5265H	Thromboplastin LI	55983

I, the undersigned declare that the devices registered against the above GMDN Classification Code conforms to the said Directives.

Full Name: M.J. Stephenson

Title: Managing Director

Signed:

Date: 06 Aug 2015

Tel +44 (0)191 482 8440
Fax +44 (0)191 482 8442
info@helena-biosciences.com
www.helena-biosciences.com

Helena Biosciences Europe
Queensway South, Team Valley Trading Estate,
Gateshead, Tyne and Wear, NE11 0SD,
United Kingdom

120 ML URINE CONTAINERS FOR VACUUM TUBES
CONTENITORI URINE 120 ML PER PROVETTE SOTTOVUOTO

Urine containers graduated up to 100 ml, yellow screw cap with device for suction with vacuum tubes. Label on the cap for sampling system protection. With writing surface.

Vol. 120 ml.
Dim. Ø 59 x 68 mm.
Material: polypropylene.

Contenitori per urine graduati fino a 100 ml, tappo a vite giallo con dispositivo per aspirazione con provette sottovuoto. Con etichetta applicata sul tappo per la protezione del sistema di prelievo. Con superficie di scrittura.

Vol. 120 ml.
Dim. Ø 59 x 68 mm.
Materiale: polipropilene.

COD.	SUPPLIED / *CONFEZIONE*
5120	Bulk / *Sfuso*
5120/TS	Sterile - Bulk / *Sfuso*
5120/SG	Sterile - Individually wrapped / *Confezione singola*



60 ML URINE CONTAINERS FOR VACUUM TUBES
CONTENITORI URINA 60 ML PER PROVETTE SOTTOVUOTO

Urine containers graduated up to 45 ml, yellow screw cap with device for suction with vacuum tubes. Label on the cap for sampling system protection.

Vol. 60 ml.
Dim. Ø 35 x 70 mm.
Material: polypropylene.

Contenitori per urine graduati fino a 45 ml, tappo a vite giallo con dispositivo per aspirazione con provette sottovuoto. Con etichetta applicata sul tappo per la protezione del sistema di prelievo.

Vol. 60 ml.
Dim. Ø 35 x 70 mm.
Materiale: polipropilene.

COD.	SUPPLIED / *CONFEZIONE*
5060	Bulk / *Sfuso*
5060/TS	Sterile - Bulk / *Sfuso*
5060/SG	Sterile - Individually wrapped / *Confezione singola*



150 ML URINE CONTAINERS
CONTENITORI URINE DA 150 ML

Urine containers graduated up to 100 ml, with screw cap and writing surface.

Vol. 150 ml.
Dim. Ø 58 x 72 mm.
Material: polypropylene.

Contenitori per urine graduati fino a 100 ml, con tappo a vite e superficie di scrittura.

Vol. 150 ml.
Dim. Ø 58 x 72 mm.
Materiale: polipropilene.

COD.	SUPPLIED / *CONFEZIONE*	CAP COLOUR/*COLORE TAPPO*
2120	Bulk, with separated cap / Sfuso, *con tappo a parte*	Light blue / *Azzurro*
2120/T	Bulk, with inserted cap / Sfuso, *con tappo inserito*	Light blue / *Azzurro*
2120/TS	Sterile, with inserted cap / *Sterile, con tappo inserito*	Red / *Rosso*
2120/CS	Aseptic / *Asettico* - Individually wrapped / *Confezione singola*	Red / *Rosso*
2120/SG	Sterile - Individually wrapped / *Confezione singola*	Red / *Rosso*



STRAWS WITH URINE COLLECTION DEVICE
SONDE CON DISPOSITIVO DI PRELIEVO DELLE URINE

Straws with urine collection device for vacuum test tubes. Suitable for containers without collection device. Available with straw of two sizes.

Sonde per il prelievo delle urine con provette sottovuoto da contenitori non dotati di dispositivo. Disponibili con tubicino di due lunghezze.

COD.	STRAW LENGTH / *LUNGHEZZA SONDA*	SUPPLIED / *CONFEZIONE*
31400	90 mm	Non sterile
31400/SG	90 mm	Sterile - Bags of 100 pcs / *Sacchetti da 100 pz.*
31400/SG/CS	90 mm	Sterile - Individually wrapped / *Confezione singola*
31500	170 mm	Non sterile

LNE
Le progrès, une passion à partager

Certification Médical-Santé

G MED

CERTIFICAT
CERTIFICATE OF REGISTRATION
N° 10462 rev. 6

Le LNE certifie que le système de management de la qualité développé par

LNE certifies that the quality management system developed by

ELITECH CLINICAL SYSTEMS SAS
Zone Industrielle
61500 SEES FRANCE

pour les activités
for the activities

Conception, production, contrôle et commercialisation de réactifs de chimie clinique destinés aux laboratoires d'analyses de biologie.
Validation de la combinaison réactifs et automates.

Design, production, control and sales of clinical chemistry reagents intended to be used by clinical laboratories.
Validation of the combination reagents and instruments.

réalisées sur le(s) site(s) de
performed on the location(s) of

ELITech Clinical Systems SAS
Zone industrielle - 61500 - SEES - FRA

est conforme aux exigences des normes internationales
complies with the requirements of the international standards

NF EN ISO 13485 : 2016

Début de validité */ Effective date :* **July 28th, 2017 (included)**
Valable jusqu'au */ Expiry date :* **July 27th, 2020 (included)**
Etabli le */ Issued on :* **July 27th, 2017**

Laboratoire national de métrologie et d'essais LNE

On behalf of the Certification Director
Cécile VAUGELADE
G-MED Certification Division Manager

cofrac
CERTIFICATION DE SYSTÈMES DE MANAGEMENT
Accréditation n°4-0038
Liste des sites accrédités et portée disponible sur www.cofrac.fr

GMED_SQ_SPE-V0-04-2016

LNE N° 10462-6
Ce certificat est délivré selon les règles de certification G-MED / This certificate is issued according to the rules of G-MED certification

Renouvelle le certificat 10462-5

ELITech Clinical Systems SAS
Zone industrielle
61500 Sées - France
Tél : +33 (0)2 33 81 21 00 Fax : +33 (0)2 22 28 77 51
www.elitechgroup.com

DECLARATION DE CONFORMITE CE

Nous, ELITech Clinical Systems SAS, zone industrielle 61500 SEES France, déclarons sous notre seule responsabilité que les réactifs appartenant au groupe 1 «METABOLITES DIVERS », référencés dans la liste ci-jointe, sont conformes aux exigences essentielles des annexes I et III de la Directive Européenne 98/79/CE relative aux dispositifs médicaux de diagnostic *in vitro* et au code de la santé publique.

Cette déclaration est basée sur le contenu de chaque dossier technique DOS-CE-XXXX et s'appuie sur la certification de notre système qualité selon la norme NF EN ISO 13485 : 2016 (Certification valable jusqu'au 27 juillet 2020).

(Voir liste ci-jointe).

DECLARATION OF EC CONFORMITY

We, ELITech Clinical Systems SAS, Zone Industrielle 61500 SEES France, hereby certify, under our own responsibility, that the reagents belonging to Group 1 "MISCELLANEOUS METABOLITES", such as listed hereto, conform to the essential requirements of appendices I and III of European Directive 98/79/EC, relating to in vitro diagnostic medical devices and to the public health code.

This declaration is based on the contents of each DOS-CE-XXXX technical file and is supported by the certification of our quality system according to the standard NF EN ISO 13485 : 2016 (Certification valid until July 27th , 2020).

(See attached list).

DECLARACIÓN CE DE CONFORMIDAD

Nosotros, ELITech Clinical Systems SAS, Zone Industrielle 61500 SEES France, declaramos bajo nuestra única responsabilidad que los reactivos pertenecientes al grupo 1 "METABÓLICOS VARIOS ", referenciados en la lista adjunta, son conformes con los requisitos esenciales de los anexos I y III de la Directiva Europea 98/79/CE sobre dispositivos médicos para diagnóstico in vitro y el código de salud pública.

Esta declaración se basa en el contenido de cada DOS-CE-XXXX técnica y está respaldado por la certificación de nuestro sistema de calidad según la norma NF EN ISO 13485 : 2016 (Certificación válida hasta el 27 de Julio 2020).

(Ver lista adjunta)

Sées, le 18 Mai 2018

Valérie GOURDON,
Responsable des Affaires Réglementaires
Regulatory Affairs Manager
Responsable de los Asuntos Reglementarios

ELITech Clinical Systems SAS
Zone Industrielle
61500 SEES - France
Tél : +33(0)2 33 81 21 00 - Fax : +33(0)2 33 28 77 51
SIRET 318 365 228 00036

Cécile GOUBAULT,
Directeur Général Délégué
Managing Director
Directora General

ELITech Clinical Systems SAS
Zone industrielle
61500 Sées - France
Tél : +33 (0)2 33 81 21 00 Fax : +33 (0)2 22 28 77 51
www.elitechgroup.com

GROUPE 1 - METABOLITES DIVERS
GROUP 1 - MISCELLANEOUS METABOLITES
GRUPO 1 – METABÓLICOS VARIOS

DESIGNATION DU REACTIF/ REAGENT DESIGNATION/ DESIGNACIÓN DE REACTIVO	REFERENCES/ REFERENCIAS	NOM DU DOSSIER CE/ EC FILE NAME/ NOMBRE DEL ARCHIVO CE	Code GMDN/ GMDN Code/ Codigo GMDN
ALBUMIN	ALBU-0600/0700/0250	DOS-CE-ALBU_R&Std	53597
ALBUMIN ENVOY	ALBU-0850		
BILIRUBIN DIRECT 4+1	BIDI-0600/0250	DOS-CE-BILI 4+1	53233
BILIRUBIN TOTAL 4+1	BITO-0600/0250		53229
BILIRUBIN TOTAL & DIRECT 4+1	BITD-0600		53229/53233
CREATININE ENVOY	CRSL-0850	DOS-CE-CRSL	53250
CREATININE JAFFE	CRCO-0600/0700	DOS-CE-CRCO_R&Std	53251
CREATININE PAP SL	CRSL-0630/0250	DOS-CE-CRSL	53250
DIRECT BILIRUBIN ENVOY	BIDV-0850	DOS-CE-BIDV	53233
GLUCOSE ENVOY	GPSL-0850	DOS-CE-GPSL_R&Std	53301
GLUCOSE HK SL	GHSL-0600/0250	DOS-CE-GHSL	
GLUCOSE PAP SL	GPSL-0495/0500/0700/ 0507/0707/0250/0455/0497	DOS-CE-GPSL_R&Std	
HEMOGLOBIN	HEMO-0400	DOS-CE-HEMO	32430
IRON TIBC	FECA-0050	DOS-CE-TIBC	53904
LACTATE	LACT-0100	DOS-CE-LACT	53342
MICROPROTEIN PLUS	PRTU-0600/0250	DOS-CE-PRTU_R&Std	53481
PHOSPHORUS	PHOS-0600/0230	DOS-CE-PHOS_R&Std	59123
PHOSPHORUS ENVOY	PHOS-0850		
TOTAL BILIRUBIN ENVOY	BITV-0850	DOS-CE-BITV	53229
TOTAL PROTEIN	PRTB-0600	DOS-CE-PRTB	53985
TOTAL PROTEIN ENVOY	PROB-0850	DOS-CE-PROB_R&Std	
TOTAL PROTEIN PLUS	PROB-0600/0700/0250		
UREA ENVOY	URSL-0850	DOS-CE-URSL_R&Std	53587
UREA UV	URUV-0400	DOS-CE-URUV	
UREA UV SL	URSL-0400/0420/0500 0407/0427/0507/0250/0455	DOS-CE-URSL_R&Std	
URIC ACID	ACUR-0200/0400	DOS-CE-ACUR	53583
URIC ACID ENVOY	AUVD-0850	DOS-CE-AUVD	
URIC ACID MONO SL	AUML-0420/0500/0700/ 0427/0497/0507/0707/0250	DOS-CE-AUML_R&Std	
URIC ACID SL	AUSL-0250	DOS-CE-AUSL	

ELITech Clinical Systems SAS
Zone Industrielle
61500 SEES - France
Tél : +33(0)2 33 81 21 00 - Fax : +33(0)2 33 28 77 51
SIRET 318 365 228 00036

Société par actions simplifiée au capital de 1 219 592,14€ – SIREN : 318 365 228 – RCS ALENCON

ELITech Clinical Systems SAS
Zone Industrielle
61500 Sées - France
Tél : +33 (0)2 33 81 21 00 Fax : +33 (0)2 22 28 77 51
www.elitechgroup.com

DECLARATION DE CONFORMITE CE

Nous, ELITech Clinical Systems SAS, zone industrielle 61500 SEES France, déclarons sous notre seule responsabilité que les réactifs appartenant au groupe 4 «LIPIDES », référencés dans la liste ci-jointe, sont conformes aux exigences essentielles des annexes I et III de la Directive Européenne 98/79/CE relative aux dispositifs médicaux de diagnostic *in vitro* et au code de la santé publique.

Cette déclaration est basée sur le contenu de chaque dossier technique DOS-CE-XXXX et s'appuie sur la certification de notre système qualité selon la norme NF EN ISO 13485 : 2016 (Certification valable jusqu'au 27 juillet 2020).

(Voir liste ci-jointe).

DECLARATION OF EC CONFORMITY

We, ELITech Clinical Systems SAS, Zone Industrielle 61500 SEES France, hereby certify, under our own responsibility, that the reagents belonging to Group 4 "LIPIDS", such as listed hereto, conform to the essential requirements of appendices I and III of European Directive 98/79/EC, relating to in vitro diagnostic medical devices and to the public health code.

This declaration is based on the contents of each DOS-CE-XXXX technical file and is supported by the certification of our quality system according to the standard NF EN ISO 13485 : 2016 (Certification valid until July 27th , 2020).

(See attached list).

DECLARACIÓN CE DE CONFORMIDAD

Nosotros, ELITech Clinical Systems SAS, Zone Industrielle 61500 SEES France, declaramos bajo nuestra única responsabilidad que los reactivos pertenecientes al grupo 4 "LÍPIDOS ", referenciados en la lista adjunta, son conformes con los requisitos esenciales de los anexos I y III de la Directiva Europea 98/79/CE sobre dispositivos médicos para diagnóstico in vitro y el código de salud pública.

Esta declaración se basa en el contenido de cada DOS-CE-XXXX técnica y está respaldado por la certificación de nuestro sistema de calidad según la norma NF EN ISO 13485 : 2016 (Certificación válida hasta el 27 de Julio 2020).

(Ver lista adjunta)

Sées, le 28 Juillet 2017

Valérie GOURDON,
Responsable des Affaires Réglementaires
Regulatory Affairs Manager
Responsable de los Asuntos Reglementarios

Cécile GOUBAULT,
Directeur Général Délégué
Managing Director
Directora General

ELITech Clinical Systems SAS
Zone Industrielle
61500 SEES - France
TEL : +33(0)2 33 81 21 00 - Fax : +33(0)2 33 28 77 51
SIRET 318 365 228 00036

ELITech Clinical Systems SAS
Zone industrielle
61500 Sées - France
Tél : +33 (0)2 33 81 21 00 Fax : +33 (0)2 22 28 77 51
www.elitechgroup.com

GROUPE 4 – LIPIDES
GROUP 4 – LIPIDS
GRUPO 4 – LÍPIDOS

DESIGNATION DU REACTIF/ REAGENT DESIGNATION/ DESIGNACIÓN DE REACTIVO	REFERENCES/ REFERENCIAS	NOM DU DOSSIER CE/ EC FILE NAME/ NOMBRE DEL ARCHIVO CE	Code GMDN/ GMDN Code/ Codigo GMDN
CHOLESTEROL	CHOL-0220/0420	DOS-CE-CHOL	53359
CHOLESTEROL ENVOY	CHSL-0850	DOS-CE-CHSL	
CHOLESTEROL SL	CHSL-0495/0500/0700/ 0507/0707/0250/0455/0497		
CHOLESTEROL HDL SL 2G	HDLL-0230/0380/0390	DOS-CE-HDLL	53391
CHOLESTEROL LDL SL 2G	LDLL-0230/0380/0390	DOS-CE-LDLL	53395
HDL CHOLESTEROL	HDLC-0060	DOS-CE-HDLC	53391
HDL CHOLESTEROL ENVOY	HDLL-0850	DOS-CE-HDLL	
LDL CHOLESTEROL ENVOY	LDLL-0850	DOS-CE-LDLL	53395
TRIGLYCERIDES	TRIG-0200/0400	DOS-CE-TRIG	53460
TRIGLYCERIDES ENVOY	TGML-0850	DOS-CE-TGMLN	
TRIGLYCERIDES MONO SL NEW	TGML-0425/0495/0515/ 0700/0427/0517/0707/0497		
TRIGLYCERIDES SL	TGML-0250/0455		

ELITech Clinical Systems SAS
Zone Industrielle
61500 SEES - France
TEL : +33(0)2 33 81 21 00 - Fax : +33(0)2 33 28 77 51
SIRET 318 365 228 00036

Société par actions simplifiée au capital de 1 219 592,14€ – SIREN : 318 365 228 – RCS ALENCON

ELITech Clinical Systems SAS
Zone industrielle
61500 Sées - France
Tél : +33 (0)2 33 81 21 00 Fax : +33 (0)2 22 28 77 51
www.elitechgroup.com

DECLARATION DE CONFORMITE CE

Nous, ELITech Clinical Systems SAS, zone industrielle 61500 SEES France, déclarons sous notre seule responsabilité que les réactifs appartenant au groupe 5 «CONTRÔLES/ CALIBRANTS/ STANDARDS », référencés dans la liste ci-jointe, sont conformes aux exigences essentielles des annexes I et III de la Directive Européenne 98/79/CE relative aux dispositifs médicaux de diagnostic *in vitro* et au code de la santé publique.

Cette déclaration est basée sur le contenu de chaque dossier technique DOS-CE-XXXX et s'appuie sur la certification de notre système qualité selon la norme NF EN ISO 13485 : 2016 (Certification valable jusqu'au 27 juillet 2020).

(Voir liste ci-jointe).

DECLARATION OF EC CONFORMITY

We, ELITech Clinical Systems SAS, Zone Industrielle 61500 SEES France, hereby certify, under our own responsibility, that the reagents belonging to Group 5, "CONTROLS/ CALIBRATORS/ STANDARDS", such as listed hereto, conform to the essential requirements of appendices I and III of European Directive 98/79/EC, relating to in vitro diagnostic medical devices and to the public health code.

This declaration is based on the contents of each DOS-CE-XXXX technical file and is supported by the certification of our quality system according to the standard NF EN ISO 13485 : 2016 (Certification valid until July 27th , 2020).

(See attached list).

DECLARACIÓN CE DE CONFORMIDAD

Nosotros, ELITech Clinical Systems SAS, Zone Industrielle 61500 SEES France, declaramos bajo nuestra única responsabilidad que los reactivos pertenecientes al grupo 5 "CONTROLES/ CALIBRADORES/ ESTÁNDARES", referenciados en la lista adjunta, son conformes con los requisitos esenciales de los anexos I y III de la Directiva Europea 98/79/CE sobre dispositivos médicos para diagnóstico in vitro y el código de salud pública.

Esta declaración se basa en el contenido de cada DOS-CE-XXXX técnica y está respaldado por la certificación de nuestro sistema de calidad según la norma NF EN ISO 13485 : 2016 (Certificación válida hasta el 27 de Julio 2020).

(Ver lista adjunta)

Sées, le 28 Juillet 2017

Valérie GOURDON,
Responsable des Affaires Réglementaires
Regulatory Affairs Manager
Responsable de los Asuntos Reglementarios

Cécile GOUBAULT,
Directeur Général Délégué
Managing Director
Directora General

ELITech Clinical Systems SAS
Zone Industrielle
61500 SEES - France
Tél : +33(0)2 33 81 21 00 - Fax : +33(0)2 33 28 77 51
SIRET 318 365 228 00085

ELITech Clinical Systems SAS
Zone industrielle
61500 Sées - France
Tél : +33 (0)2 33 81 21 00 Fax : +33 (0)2 22 28 77 51
www.elitechgroup.com

GROUPE 5 – CONTROLES/CALIBRANTS/STANDARDS
GROUP 5 – CONTROLS/CALIBRATORS/STANDARDS
GRUPO 5 – CONTROLES/CALIBRADORES/ESTÁNDARES

DESIGNATION DU REACTIF/ REAGENT DESIGNATION/ DESIGNACIÓN DE REACTIVO	REFERENCES/ REFERENCIAS	NOM DU DOSSIER CE/ EC FILE NAME/ NOMBRE DEL ARCHIVO CE	Code GMDN/ GMDN Code/ Codigo GMDN
CHOLESTEROL HDL 2G CALIBRATOR	HDLL-0011/0041	DOS-CE-HDLL-CAL	44696
CHOLESTEROL LDL 2G CALIBRATOR	LDLL-0011/0041	DOS-CE-LDLL-CAL	41728
CHOLESTEROL Standard 200 mg/dL	CHOL-0055	DOS-CE-CHOL200	44698
CK-MB CONTROL	CKMB-0900	DOS-CE-CKMB-CT	44693
CREATININE Standard 2 mg/dL	CREN-0055	DOS-CE-CREN2	44700
ELICAL 2	CALI-0550	DOS-CE-CALI2	47868
ELITROL I	CONT-0060	DOS-CE-ELIT I	47869
ELITROL II	CONT-0160	DOS-CE-ELIT II	
GLUCOSE Standard 100 mg/dL	GLUP-0055	DOS-CE-GLUP100	41818
ISE CONTROL I	ISCT-0046	DOS-CE-ISCT	47869
ISE CONTROL II	ISCT-0047		
MICROPROTEIN PLUS Standard 100 mg/dL	PRTU-0022	DOS-CE-PRTU100	53482
TRIGLYCERIDES Standard 200 mg/dL	TRIG-0055	DOS-CE-TRIG200	44702
UREA Standard 50 mg/dL	URUV-0055	DOS-CE-URUV50	53588
URIC ACID Standard 6 mg/dL	ACUR-0055	DOS-CE-ACUR6	44704

ELITech Clinical Systems SAS
Zone Industrielle
61500 SEES - France
Tél : +33(0)2 33 81 21 00 - Fax : +33(0)2 33 28 77 51
SIRET 318 365 228 00085

Société par actions simplifiée au capital de 1 219 592,14€ – SIREN : 318 365 228 – RCS ALENCON

DCCE-G5 – V23 – Juillet /July /Julio 2017

DECLARATION OF CONFORMITY

1) Manufacturer *(Name, department)*: **Monobind Inc.**

Address: **100 North Pointe, LAKE FOREST, CA 92630. UNITED STATES**

and

2) European authorized representative: **CEpartner4U BV,**

Address: **ESDOORNLAAN 13, 3951DB MAARN, THE NETHERLANDS**;
(on product labels printed as:
CEpartner4U , ESDOORNLAAN 13, 3951DB MAARN, THE NETHERLANDS Tel.: +31 (0)6 516 536 26;
or as: CEpartner4U, 3951DB; 13, NL tel: +31 (0)6 – 516.536.26)

3) Product(s) *(name, type or model/batch number, etc.)*:

Immunoassay products;
ELISA,
CLIA,
Control,
Instruments (see appendix)

4) The product(s) described above is in conformity with:

Document No.	Title	Edition / Date of issue
L 331; 98/79/EC	In-Vitro-Diagnostic Directive	1998-10-27

5) Additional information *(conformity procedure, Notified Body, CE certificate, etc.)*:

Conformity assessment procedure for CE marking: IVD Directive, Annex III

Lake Forest, USA;2011-09-27 ---------- A Shatola ----------

Tony Shatola; QA Director, Monobind Inc.

(Place & date of issue (yyyy-mm-dd)) *(name, function and signature of manufacturer)*

Maarn, NL; 2011-09-27 ----------

Olga Teirlinck; Consultant, CEpartner4U BV

(Place & date of issue (yyyy-mm-dd)) *(name; function and signature of authorized representative)*

Appendix

Date: 2011-09-26

Device types	Item# ELISA	Item# CLIA	Item# Control	Item# Instrument	EDMS code	Risk Class	Certificate #	First date of CE-marking
Thyroid								
T3 – Triiodothyronine	125-300	175-300			12.04.01.05.00	Low		2005-11-11
fT3 – Free Triiodothyronine	1325-300	1375-300			12.04.01.01.00	Low		2005-11-11
T4 – Thyroxine	225-300	275-300			12.04.01.07.00	Low		2005-11-11
fT4 – Free Thyroxine	1225-300	1275-300			12.04.01.02.00	Low		2005-11-11
TSH – Thyrotropin	325-300	375-300			12.04.01.11.00	Low		2005-11-11
Rapid TSH – Rapid Thyrotropin	6025-300	6075-300			12.04.01.11.00	Low		2010-06-29
T3U – Triiodothyronine Uptake	525-300	575-300			12.04.01.06.00	Low		2005-11-11
TBG – Thyroxine-Binding Globulin	3525-300	3575-300			12.04.01.09.00	Low		2005-11-11
Tg – Thyroglobulin	2225-300	2275-300			12.04.01.08.00	Low		2005-11-11
T3, T4 & TSH – Triiodothyronine, Thyroxine & Thyrotropin Combo (VAST)	8025-300	8075-300			12.04.01.01.00	Low		2005-11-11
T3 – Triiodothyronine (SBS)	8125-300	8175-300			12.04.01.01.00	Low		2010-06-29
T4- Thyroxine (SBS)	8225-300	8275-300			12.04.01.01.00	Low		2010-06-29
fT3, fT4 & TSH – Free Triiodothyronine, Free Thyroxine & Thyrotropin Combo (VAST)	7025-300	7075-300			12.04.01.01.00	Low		2010-06-29
Neonatal Thyroid & Genetics								
NTSH – Neonatal Thyrotropin	3425-300	3475-300			12.04.01.90.00	Low		2005-11-11
NT4 – Neonatal Thyroxine	2625-300	2675-300			12.04.01.12.00	Low		2005-11-11
N 17OHP – Neonatal 17 OH Progesterone	5525-300				12.05.01.07	Low		2008-02-01
Biotinidase	8825-300				12 07 02 90 00	Low		2011-09-26
Autoimmune Thyroid								
Anti-Tg – Anti-Thyroglobulin Antigen	1025-300	1075-300			12.10.03.04.00	Low		2005-11-11
Anti-TPO – Anti-Thyroperoxidase Antigen	1125-300	1175-300			12.10.03.01.00	Low		2005-11-11
Fertility & Prenatal								
LH – Lutropin	625-300	675-300			12.05.01.05.00	Low		2005-11-11
FSH – Follitropin	425-300	475-300			12.05.01.04.00	Low		2005-11-11
PRL – Prolactin	725-300	775-300			12.05.01.08.00	Low		2005-11-11
PRL – Prolactin Sequential	6025-300	6075-300			12.05.01.08.00	Low		2005-11-11
hCG – Human Chorionic Gonadotropin	825-300	875-300			12.05.02.05.00	Low		2005-11-11
Rapid hCG – Rapid Human Chorionic Gonadotropin	3325-300				12.05.02.05.00	Low		2005-11-11
FSH, LH, hCG, sPRL Combo (VAST)	8325-300	8375-300			12.05.01.90.00	Low		2006-08-24
AFP, hCG, uE3 Combo (VAST)	8525-300	8575-300			12.05.01.90.00	Low		2010-06-29
Steroid								
Cortisol	3625-300	3675-300			12.06.02.04.00	Low		2005-11-11
DHEA-S – Dehydroepiandrosterone sulfate	5125-300	5175-300			12.05.01.02.00	Low		2010-06-29
DHEA - Dehydroepiandrosterone	7425-300	7475-300			12.05.01.02.00	Low		2011-09-26

Device types	Item# ELISA	Item# CLIA	Item# Control	Item# Instrument	EDMS code	Risk Class	Certificate #	First date of CE-marking
E2 – Estradiol	4925-300	4975-300			12.05.01.03.00	Low		2010-06-29
uE3 – Estriol, Unconjugated	5025-300	5075-300			12.05.02.02.00	Low		2010-06-29
Progesterone	4825-300	4875-300			12.05.01.06.00	Low		2010-06-29
Testosterone	3725-300	3775-300			12.05.01.10.00	Low		2007-11-01
Free Testosterone	5325-300	5375-300			12.05.01.10.00	Low		2010-06-29
17OHP - 17-Hydroxyprogesterone	5225-300	5275-300			12.05.01.07.00	Low		2010-06-29
17OHP - 17-Hydroxyprogesterone Ext. Range	9925-300	9975-300			12.05.01.07.00	Low		2010-10-18
Vitamin D3 – 25-Hydroxyvitamin D3	7725-300	7775-300			12.06.03.10.00	Low		2011-09-26
Growth & Bone Metabolism								
hGH - Human Growth Hormone	1725-300	1775-300			12.06.04.02.00	Low		2005-11-11
PTH - Parathyroid Hormone	7825-300	7875-300			12.06.03.13.00	Low		2011-09-26
Diabetes								
Insulin	2425-300	2475-300			12.06.01.03.00	Low		2005-11-11
Insulin Rapid	5825-300				12.06.01.03.00	Low		2010-06-29
C-peptide	2725-300	2775-300			12.06.01.01.00	Low		2005-11-11
Insulin & C-peptide Combo (VAST)	7325-300	7375-300			12.06.01.03.00	Low		2005-11-11
Cardiac Markers								
CKMB – Circulating Creatine Kinase (MB)	2925-300	2975-300			12.13.01.02.00	Low		2005-11-11
CTnI – Troponin I	3825-300	3875-300			12.13.01.07.00	Low		2005-11-11
DIG – Digoxin	925-300	975-300			12.08.01.01.00	Low		2005-11-11
HS-CRP – High Sensitivity C-Reactive Protein	3125-300	3175-300			12.13.01.90.00	Low		2005-11-11
Myoglobin	3225-300	3275-300			12.13.01.05.00	Low		2005-11-11
Infectious Diseases								
IgG – Anti/H. Pylori	1425-300	1475-300			15.01.04.03.00	Low		2005-11-11
IgM – Anti/H. Pylori	1525-300	1575-300			15.01.04.03.00	Low		2005-11-11
IgA – Anti/H. Pylori	1625-300	1675-300			15.01.04.03.00	Low		2005-11-11
Cancer Markers								
AFP – Alpha-Fetoprotein	1925-300	1975-300			12.03.90.01.00	Low		2005-11-11
CA 125 Ovarian Cancer Antigen	3025-300	3075-300			12.03.01.06.00	Low		2005-11-11
CA 15-3 Breast Cancer Antigen	5625-300	5675-300			12.03.01.02.00	Low		2010-06-29
CA 19-9 - Pancreatic Cancer Antigen	3925-300	3975-300			12.03.01.03.00	Low		2005-11-11
CEA – Carcinoembryonic Antigen	1825-300	1875-300			12.03.01.31.00	Low		2005-11-11
CEA - Carcinoembryonic Antigen Next Generation	4625-300	4675-300			12.03.01.31.00	Low		2010-06-29
fβhCG – Free Beta Human Chorionic Gonadotropin	2025-300	2075-300			12.03.01.90.00	Low		2005-11-11
Allergy & Anemia								
Ferritin	2825-300	2875-300			12.07.01.02.00	Low		2005-11-11
Folate	7525-300	7575-300			12.07.01.03.00	Low		2010-06-29
IgE – Immunoglobulin E	2525-300	2575-300			12.02.01.02.00	Low		2005-11-11
sTfR - Transferrin Soluble Receptor	8625-300	8675-300			12.07.01.06.00	Low		2010-06-29
Vitamin B12	7625-300	7675-300			12.07.02.04.00	Low		2011-09-26

Miscellaneous Controls								
Anti-Tg & Anti-TPO – Positive & Negative - Anti-Thyroglobulin, Anti-Thyroperoxidase			AIT-101		12.50.01.16.00	Low		2010-06-29
High Level Fertility Control – Single Level – Progesterone, Estradiol, Human Chorionic Gonadotropin			FC-300		12.50.01.16.00	Low		2010-06-29
Maternal Control – Tri Level - Human Chorionic Gonadotropin, Free Beta Human Chorionic Gonadotropin Subunit, Alpha Feta Protein, Estriol			MC-300		12.50.01.16.00	Low		2010-06-29
Thyroglobulin Control – Tri Level			TG-300		12.50.01.16.00	Low		2010-06-29
H. Pylori IgG Control – Positive & Negative			HPy-IgG-300		12.50.01.16.00	Low		2010-06-29
Miscellaneous Instruments								
IC hardware + dedicated accessories + software – Autoplex ELISA Analyzer & CLIA Processor				IN006	21.02.10.01	Low		2010-06-29
IC hardware + dedicated accessories + software – Lumax Chemiluminescence Strip Reader				IN001	21.02.10.01	Low		2006-08-24
IC hardware + dedicated accessories + software – Neo-Lumax Chemiluminescence Strip Reader				IN010	21.02.10.01	Low		2011-09-26
IC hardware + dedicated accessories + software – Impulse 2 Chemiluminescence Strip Reader				IN005	21.02.10.01	Low		2006-08-24
IC hardware + dedicated accessories + software – Impulse 3 Chemiluminescence Strip Reader				IN007	21.02.10.01	Low		2010-06-29
IC hardware + dedicated accessories + software – Lumax96 Chemiluminescence Plate Reader				IN004	21.02.10.01	Low		2007-03-01
IC hardware + dedicated accessories + software – LuMatic Chemiluminescence Plate Reader				IN008	21.02.10.01	Low		2011-09-26
IC hardware + dedicated accessories + software – Eldex 3.8 ELISA Strip Reader				IN003	21.02.10.01	Low		2007-09-10
IC hardware + dedicated accessories + software – Neo-Eldex ELISA Strip Reader				IN009	21.02.10.01	Low		2011-09-26
IC hardware + dedicated accessories + software – Mircoplate Washer				IN002	21.02.10.01	Low		2010-06-29

Monobind Inc.
Lake Forest, CA 92630, USA

AccuBind
ELISA Microwells

Thyrotropin (TSH) Test System
Product Code: 325-300

1.0 INTRODUCTION

Intended Use: The Quantitative Determination of Thyrotropin Concentration in Human Serum by a Microplate Immunoenzymometric assay

2.0 SUMMARY AND EXPLANATION OF THE TEST

Measurement of the serum concentration of thyrotropin (TSH), a glycoprotein with a molecular weight of 28,000 Daltons and secreted from the anterior pituitary, is generally regarded as the most sensitive indicator available for the diagnosis of primary and secondary (pituitary) hypothyroidism (1, 2). The structure of human TSH is similar to that of the pituitary and placental gonadotropins, consisting of an 89-amino acid α-subunit which is similar or identical between these hormones and a 115-amino acid β-subunit, which apparently confers hormonal specificity. The production of the 2 subunits is separately regulated with apparent excess production of the α-subunit. The TSH molecule has a linear structure consisting of the protein core with carbohydrate side chains; the latter accounts for 16% of the molecular weight.

TSH measurements are equally useful in differentiating secondary and tertiary (hypothalamic) hypothyroidism from the primary thyroid disease. TSH release from the pituitary is regulated by thyrotropin releasing factor (TRH), which is secreted by the hypothalamus, and by direct action of T4 and triiodothyronine (T3), the thyroid hormones, at the pituitary. Increase levels of T3 and T4 reduces the response of the pituitary to the stimulatory effects of TRH. In secondary and tertiary hypothyroidism, concentrations of T4 are usually low and TSH levels are generally low or normal. Either pituitary TSH deficiency (secondary hypothyroidism) or insufficiency of stimulation of the pituitary by TRH (tertiary hypothyroidism) causes this. The TRH stimulation test differentiates these conditions. In secondary hypothyroidism, TSH response to TRH is blunted while a normal or delayed response is obtained in tertiary hypothyroidism.

Further, the advent of immunoenzymometric assays has provided the laboratory with sufficient sensitivity to enable the differentiating of hyperthyroidism from euthyroid population and extending the usefulness of TSH measurements. This method is a second-generation assay, which provides the means for discrimination in the hyperthyroid-euthyroid range. The functional sensitivity (<20% between assay CV) of the one-hour procedure is 0.195 µIU/ml while the two-hour procedure has a functional sensitivity of 0.095µIU/ml (3).

In this method, TSH calibrator, patient specimen or control is first added to a streptavidin coated well. Biotinylated monoclonal and enzyme labeled antibodies are added and the reactants mixed. Reaction between the various TSH antibodies and native TSH forms a sandwich complex that binds with the streptavidin coated to the well.

After the completion of the required incubation period, the antibody bound enzyme-thyrotropin conjugate is separated from the unbound enzyme-thyrotropin conjugate by aspiration or decantation. The activity of the enzyme present on the surface of the well is quantitated by reaction with a suitable substrate to produce color.
The employment of several serum references of known thyrotropin levels permits construction of a dose response curve of activity and concentration. From comparison to the dose response curve, an unknown specimen's activity can be correlated with thyrotropin concentration.

3.0 PRINCIPLE

Immunoenzymometric assay (TYPE 3):
The essential reagents required for an immunoenzymometric assay include high affinity and specificity antibodies (enzyme conjugated and immobilized), with different and distinct epitope recognition, in excess, and native antigen. In this procedure, the immobilization takes place during the assay at the surface of a microplate well through the interaction of streptavidin coated on the well and exogenously added biotinylated monoclonal anti-TSH antibody.
Upon mixing monoclonal biotinylated antibody, the enzyme-labeled antibody and a serum containing the native antigen, reaction results between the native antigen and the antibodies, without competition or steric hindrance, to form a soluble sandwich complex. The interaction is illustrated by the following equation:

$$^{Enz}Ab_{(p)} + Ag_{TSH} + {}^{Btn}Ab_{(m)} \underset{k_{-a}}{\overset{k_a}{\rightleftharpoons}} {}^{Enz}Ab_{(p)}\text{-}Ag_{TSH}\text{-}{}^{Btn}Ab_{(m)}$$

$^{Btn}Ab_{(m)}$ = Biotinylated Monoclonal Antibody (Excess Quantity)
Ag_{TSH} = Native Antigen (Variable Quantity)
$^{Enz}Ab_{(p)}$ =Enzyme -Polyclonal Antibody (Excess Quantity)
$^{Enz}Ab_{(p)}\text{-}Ag_{TSH}\text{-}{}^{Btn}Ab_{(m)}$ = Antigen-Antibodies Sandwich Complex
k_a = Rate Constant of Association
k_{-a} = Rate Constant of Dissociation

Simultaneously, the complex is deposited to the well through the high affinity reaction of streptavidin and biotinylated antibody. This interaction is illustrated below:

$^{Enz}Ab_{(p)}\text{-}Ag_{TSH}\text{-}{}^{Btn}Ab_{(m)}$ +Streptavidin$_{CW}$ ⇒ immobilized complex
Streptavidin$_{CW}$ = Streptavidin immobolized on well

Immobilized complex = sandwich complex bound to the well surface

After equilibrium is attained, the antibody-bound fraction is separated from unbound antigen by decantation or aspiration. The enzyme activity in the antibody-bound fraction is directly proportional to the native antigen concentration. By utilizing several different serum references of known antigen values, a dose response curve can be generated from which the antigen concentration of an unknown can be ascertained.

4.0 REAGENTS

Materials Provided:

A. **Thyrotropin Calibrators – 1ml/vial - Icons A-G**
Seven (7) vials of references for TSH Antigen at levels of 0(A), 0.5(B), 2.5(C), 5.0(D), 10(E), 20(F) and 40(G) µIU/ml. Store at 2-8°C. A preservative has been added.
Note: The calibrators, human serum based, were calibrated using a reference preparation, which was assayed against the WHO 2nd IRP 80/558.

B. **TSH Enzyme Reagent – 13ml/vial - Icon E**
One (1) vial containing enzyme labeled affinity purified polyclonal goat antibody, biotinylated monoclonal mouse IgG in buffer, dye, and preservative. Store at 2-8°C.

C. **Streptavidin Coated Plate – 96 wells - Icon ⇓**
One 96-well microplate coated with streptavidin and packaged in an aluminum bag with a drying agent. Store at 2-8°C.

D. **Wash Solution Concentrate – 20 ml - Icon ♦**
One (1) vial containing a surfactant in buffered saline. A preservative has been added. Store at 2-8°C.

E. **Substrate A – 7ml/vial - Icon S^A**
One (1) bottle containing tetramethylbenzidine (TMB) in buffer. Store at 2-8°C.

F. **Substrate B – 7ml/vial - Icon S^B**
One (1) bottle containing hydrogen peroxide (H_2O_2) in buffer. Store at 2-8°C.

G. **Stop Solution – 8ml/vial - Icon STOP**
One (1) bottle containing a strong acid (1N HCl). Store at 2-8°C.

H. **Product Instructions.**

Note 1: Do not use reagents beyond the kit expiration date.
Note 2: Avoid extended exposure to heat and light. Opened reagents are stable for sixty (60) days when stored at 2-8°C. Kit and component stability are identified on the label.
Note 3: Above reagents are for a single 96-well microplate.

4.1 Required But Not Provided:
1. Pipette(s) capable of delivering 50µl and 100µl volumes with a precision of better than 1.5%.
2. Dispenser(s) for repetitive deliveries of 0.100ml and 0.350ml volumes with a precision of better than 1.5% (optional).
3. Microplate washer or a squeeze bottle (optional).
4. Microplate Reader with 450nm and 620nm wavelength absorbance capability.
5. Absorbent Paper for blotting the microplate wells.
6. Plastic wrap or microplate cover for incubation steps.
7. Vacuum aspirator (optional) for wash steps.
8. Timer.
9. Storage container for storage of wash buffer.
10. Distilled or deionized water.
11. Quality Control Materials.

5.0 PRECAUTIONS

For In Vitro Diagnostic Use
Not for Internal or External Use in Humans or Animals

All products that contain human serum have been found to be non-reactive for Hepatitis B Surface antigen, HIV 1&2 and HCV antibodies by FDA required tests. Since no known test can offer complete assurance that infectious agents are absent, all human serum products should be handled as potentially hazardous and capable of transmitting disease. Good laboratory procedures for handling blood products can be found in the Center for Disease Control / National Institute of Health, "Biosafety in Microbiological and Biomedical Laboratories," 2nd Edition, 1988, HHS.

Safe disposal of kit components must be according to local regulatory and statutory requirement.

6.0 SPECIMEN COLLECTION AND PREPARATION

The specimens shall be blood, serum in type, and the usual precautions in the collection of venipuncture samples should be observed. For accurate comparison to established normal values, a fasting morning serum sample should be obtained. The blood should be collected in a plain redtop venipuncture tube without additives or gel barrier. Allow the blood to clot. Centrifuge the specimen to separate the serum from the cells.

Samples may be refrigerated at 2-8°C for a maximum period of five (5) days. If the specimen(s) cannot be assayed within this time, the sample(s) may be stored at temperatures of -20°C for up to 30 days. Avoid use of contaminated devices. Avoid repetitive freezing and thawing. When assayed in duplicate, 0.100 ml of the specimen is required.

7.0 QUALITY CONTROL

Each laboratory should assay controls at levels in the low, normal, and elevated range for monitoring assay performance. These controls should be treated as unknowns and values determined in every test procedure performed. Quality control charts should be maintained to follow the performance of the supplied reagents. Pertinent statistical methods should be employed to ascertain trends. The individual laboratory should set acceptable assay performance limits. Other parameters that should be monitored include the 80, 50 and 20% intercepts of the dose response curve for run-to-run reproducibility. In addition, maximum absorbance should be consistent with past experience. Significant deviation from established performance can indicate unnoticed change in experimental conditions or degradation of kit reagents. Fresh reagents should be used to determine the reason for the variations.

8.0 REAGENT PREPARATION:

1. **Wash Buffer**
Dilute contents of wash concentrate to 1000ml with distilled or de-ionized water in a suitable storage container. Store at 2-30°C for up to 60 days.
2. **Working Substrate Solution**
Pour the contents of the amber vial labeled Solution 'A' into the clear vial labeled Solution 'B'. Place the yellow cap on the clear vial for easy identification. Mix and label accordingly. Store at 2 - 8°C.

Note1 : Do not use the working substrate if it looks blue.
Note 2: Do not use reagents that are contaminated or have bacteria growth.

9.0 TEST PROCEDURE

Before proceeding with the assay, bring all reagents, serum references and controls to room temperature (20 - 27 °C).
"Test Procedure should be performed by a skilled individual or trained professional"

1. Format the microplates' wells for each serum reference, control and patient specimen to be assayed in duplicate. Replace any unused microwell strips back into the aluminum bag, seal and store at 2-8°C.
2. Pipette 0.050 ml (50µl) of the appropriate serum reference, control or specimen into the assigned well.
3. Add 0.100 ml (100µl) of the TSH Enzyme Reagent to each well. It is very important to dispense all reagents close to the bottom of the coated well.
4. Swirl the microplate gently for 20-30 seconds to mix and cover.
5. Incubate 60 minutes at room temperature. **
6. Discard the contents of the microplate by decantation or aspiration. If decanting, tap and blot the plate dry with absorbent paper.
7. Add 350µl of wash buffer (see Reagent Preparation Section), decant (tap and blot) or aspirate. Repeat two (2) additional times for a total of three (3) washes. An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and repeat two (2) additional times.
8. Add 0.100 ml (100µl) of working substrate solution to all wells (see Reagent Preparation Section). Always add reagents in the same order to minimize reaction time differences between wells.
DO NOT SHAKE THE PLATE AFTER SUBSTRATE ADDITION
9. Incubate at room temperature for fifteen (15) minutes.
10. Add 0.050ml (50µl) of stop solution to each well and mix gently for 15-20 seconds. Always add reagents in the same order to minimize reaction time differences between wells.
11. Read the absorbance in each well at 450nm (using a reference wavelength of 620-630nm to minimize well imperfections) in a microplate reader. The results should be read within thirty (30) minutes of adding the stop solution.

** For better low-end sensitivity (< 0.5µIU/ml), incubate 120 minutes at room temperature. The 40µIU/ml calibrator should be excluded since absorbance over 3.0 units will be experienced. Follow the remaining steps.

Note: Dilute samples reading over 40 µIU/ml by 1:5 and 1:10 with TSH '0' Calibrator. Multiply the results by the dilution factor to obtain accurate results.

10.0 CALCULATION OF RESULTS

A dose response curve is used to ascertain the concentration of thyrotropin in unknown specimens.
1. Record the absorbance obtained from the printout of the microplate reader as outlined in Example 1.
2. Plot the absorbance for each duplicate serum reference versus the corresponding TSH concentration in µIU/ml on linear graph paper (do not average the duplicates of the serum references before plotting).
3. Draw the best-fit curve through the plotted points.
4. To determine the concentration of TSH for an unknown, locate the average absorbance of the duplicates for each unknown on the vertical axis of the graph, find the intersecting point on the curve, and read the concentration (in µIU/ml) from the horizontal axis of the graph (the duplicates of the unknown may be averaged as indicated). In the following example, the average absorbance (0.775) intersects the dose response curve at (7.66 µIU/ml) TSH concentration (See Figure 1).

Note: Computer data reduction software designed for ELISA assay may also be used for the data reduction. If such software is utilized, the validation of the software should be ascertained.

EXAMPLE 1

Sample I.D.	Well Number	Abs	Mean Abs	Value (µIU/ml)
Cal A	A1	0.018	0.019	0
	B1	0.021		
Cal B	C1	0.076	0.079	0.5
	D1	0.082		
Cal C	E1	0.302	0.298	2.5
	F1	0.293		
Cal D	G1	0.556	0.567	5.0
	H1	0.577		
Cal E	A2	0.926	0.921	10
	B2	0.916		
Cal F	C2	1.610	1.619	20
	D2	1.629		
Cal G	E2	2.694	2.671	40
	F2	2.647		
Control	G2	0.800	0.775	7.66
	H2	0.751		
Patient	A3	1.391	1.383	16.65
	B3	1.375		

*The data presented in Example 1 and Figure 1 are for illustration only and should not be used in lieu of a dose response curve prepared with each assay.

Figure 1



11.0 Q.C. PARAMETERS

In order for the assay results to be considered valid the following criteria should be met:
1. The absorbance of calibrator 'G' (40 µIU/ml) should be ≥ 1.3.
2. Four out of six quality control pools should be within the established ranges.

12.0 RISK ANALYSIS

The MSDS and Risk Analysis Form for this product is available on request from Monobind Inc.

12.1 Assay Performance
1. It is important that the time of reaction in each well is held constant to achieve reproducible results.
2. Pipetting of samples should not extend beyond ten (10) minutes to avoid assay drift.
3. Highly lipemic, hemolyzed or grossly contaminated specimen(s) should not be used.
4. If more than one (1) plate is used, it is recommended to repeat the dose response curve.
5. The addition of substrate solution initiates a kinetic reaction, which is terminated by the addition of the stop solution. Therefore, the substrate and stop solution should be added in the same sequence to eliminate any time-deviation during reaction.
6. Plate readers measure vertically. Do not touch the bottom of the wells.
7. Failure to remove adhering solution adequately in the aspiration or decantation wash step(s) may result in poor replication and spurious results.
8. Use components from the same lot. No intermixing of reagents from different batches.
9. Accurate and precise pipetting, as well as following the exact time and temperature requirements prescribed are essential. Any deviation from Monobind's IFU may yield inaccurate results.
10. Patient specimens with TSH concentrations over 40µIU/ml may be diluted (1:5 or 1:10) with the '0' calibrator and re-assayed. The sample's concentration is obtained by multiplying the result by the dilution factor.
11. All applicable national standards, regulations and laws, including, but not limited to, good laboratory procedures, must be strictly followed to ensure compliance and proper device usage.
12. It is important to calibrate all the equipment e.g. Pipettes, Readers, Washers and/or the automated instruments used with this device, and to perform routine preventative maintenance.
13. Risk Analysis- as required by CE Mark IVD Directive 98/79/EC - for this and other devices, made by Monobind, can be requested via email from Monobind@monobind.com.

12.2 Interpretation
1. ***Measurement and interpretation of results must be performed by a skilled individual or trained professional.***
2. Laboratory results alone are only one aspect for determining patient care and should not be the sole basis for therapy, particularly if the results conflict with other determinants.
3. For valid test results, adequate controls and other parameters must be within the listed ranges and assay requirements.
4. If test kits are altered, such as by mixing parts of different kits, which could produce false test results, or if results are incorrectly interpreted, Monobind shall have no liability.
5. If computer controlled data reduction is used to interpret the results of the test, it is imperative that the predicted values for the calibrators fall within 10% of the assigned concentrations.
6. Serum TSH concentration is dependent upon a multiplicity of factors: hypothalamus gland function, thyroid gland function, and the responsiveness of pituitary to TRH. Thus, thyrotropin concentration alone is not sufficient to assess clinical status.
7. Serum TSH values may be elevated by pharmacological intervention. Domperiodone, amiodazon, iodide, phenobarbital, and phenytoin have been reported to increase TSH levels.
8. A decrease in thyrotropin values has been reported with the administration of propranolol, methimazol, dopamine and d-thyroxine (4).
9. Genetic variations or degradation of intact TSH into subunits may affect the binding characteristics of the antibodies and influence the final result. Such samples normally exhibit different results among various assay systems due to the reactivity of the antibodies involved.

"NOT INTENDED FOR NEWBORN SCREENING"

13.0 EXPECTED RANGES OF VALUES

A study of euthyroid adult population was undertaken to determine expected values for the TSH AccuBind™ ELISA Test System. The number and determined range are given in Table 1. A nonparametric method (95% Percentile Estimate) was used.

TABLE I
Expected Values for the TSH ELISA Test System (In µIU/ml)

Number	139	2.5 Percentile–70% Conf Int	
Low Normal	0.39	Low Range	0.28 – 0.53
High Normal	6.16	High Range	5.60 – 6.82

It is important to keep in mind that establishment of a range of values which can be expected to be found by a given method for a population of "normal"-persons is dependent upon a multiplicity of factors: the specificity of the method, the population tested and the precision of the method in the hands of the analyst. For these reasons each laboratory should depend upon the range of expected values established by the manufacturer only until an in-house range can be determined by the analysts using the method with a population indigenous to the area in which the laboratory is located.

14.0 PERFORMANCE CHARACTERISTICS

14.1 Precision
The within and between assay precisions of the TSH AccuBind™ test system were determined by analyses on three different levels of pool control sera. The number (N), mean (X) value, standard deviation (σ) and coefficient of variation (C.V.) for each of these control sera are presented in Table 2 and Table 3.

TABLE 2
Within Assay Precision (Values in µIU/ml)

Sample	N	X	σ	C.V.
Pool 1	24	0.37	0.03	8.1%
Pool 2	24	6.75	0.43	6.4%
Pool 3	24	29.30	1.94	6.6%

TABLE 3
Between Assay Precision* (Values in µIU/ml)

Sample	N	X	σ	C.V.
Pool 1	10	0.43	0.04	9.3%
Pool 2	10	6.80	0.54	7.9%
Pool 3	10	28.40	1.67	5.9%

*As measured in ten experiments in duplicate over seven days.

14.2 Sensitivity
The sensitivity (detection limit) was ascertained by determining the variability of the 0 µIU/ml serum calibrator and using the 2σ (95% certainty) statistic to calculate the minimum dose:
For 1 hr incubation = 0.078 µIU/ml
For 2 hr incubation = 0.027 µIU/ml

14.3 Accuracy
The TSH AccuBind™ ELISA test system was compared with a reference immunochemiluminescence assay. Biological specimens from hypothyroid, euthyroid and hyperthyroid populations were used (The values ranged from 0.01µIU/ml – 61µIU/ml). The total number of such specimens was 241. The least square regression equation and the correlation coefficient were computed for the TSH AccuBind™ ELISA method in comparison with the reference method. The data obtained is displayed in Table 4.

TABLE 4

Method	Mean (x)	Least Square Regression Analysis	Correlation Coefficient
This Method	4.54	y = 0.47 + 0.968 (x)	0.995
Reference	4.21		

Only slight amounts of bias between the TSH AccuBind™ ELISA method and the reference method are indicated by the closeness of the mean values. The least square regression equation and correlation coefficient indicates excellent method agreement.

14.4 Specificity
The cross-reactivity of the TSH AccuBind™ ELISA test system to selected substances was evaluated by adding the interfering substance to a serum matrix at various concentrations. The cross-reactivity was calculated by deriving a ratio between dose of interfering substance to dose of thyrotropin needed to produce the same absorbance.

Substance	Cross Reactivity	Concentration
Thyrotropin (hTSH)	1.0000	-
Follitropin (hFSH)	< 0.0001	1000ng/ml
Lutropin Hormone (hLH)	< 0.0001	1000ng/ml
Chorionic Gonadotropin(hCG)	< 0.0001	1000ng/ml

14.5 Correlation between 1 hr and 2 hr Incubation
The one- (1) hr and two (2) hr (optional) incubation procedures were compared. Thirty (30) biological specimens (ranging from 0.1 – 18.5 µIU/ml) were used. The least square regression equation and the correlation coefficient were computed for the 2 hr procedure (y) in comparison with the 1 hr method (x). Excellent agreement is evidenced by the correlation coefficient, slope and intercept: Y = 0.988 (x) + 0.119 Regression Correlation =0.998

15.0 REFERENCES

1. Hopton MR, & Harrap JJ, "Immunoradiometric assay of thyrotropin as a first line thyroid function test in the routine laboratory", *Clinical Chemistry*, 32, 691 (1986).
2. Caldwell, G et al, "A new strategy for thyroid function testing", *Lancet*, I, 1117 (1985).
3. Young DS, Pestaner LC, and Gibberman U, "Effects of Drugs on Clinical Laboratory Tests", *Clinical Chemistry*, 21, 3660 (1975).
4. Spencer, CA, et al, "Interlaboratory/Intermethod differences in Functional Sensitivity of Immunometric Assays of Thyrotropin (TSH) and Impact on Reliability of Measurement of Subnormal Concentrations of TSH", *Clinical Chemistry*, 41, 367 (1995).
5. Beck-Peccoz P, Persani L, "Variable biological activity of thyroid stimulating hormone", *Eur J Endocrinol*, 131, 331-340 (1994).
6. Bravermann, LE, "Evaluation of thyroid status in patients with thyrotoxicosis", *Clin Chem*, 42, 174-181 (1996).
7. Fisher, DA, "Physiological variations in thyroid hormones. Physiological and pathophysiological considerations", *Clin Chem*, 42, 135-139 (1996).

Revision: 3 Date: 061112 DCO: 0040
Cat #: 325-300

[illegible]		[illegible]	[illegible]	[illegible]	[illegible]
Reagent (fill)	A)	1ml set	1ml set	2ml set	2ml set x2
	B)	1 (13ml)	2 (13ml)	1 (60ml)	2 (60ml)
	C)	1 plate	2 plates	5 plates	10 plates
	D)	1 (20ml)	1 (20ml)	1 (60ml)	2 (60ml)
	E)	1 (7ml)	2 (7ml)	1 (30ml)	2 (30ml)
	F)	1 (7ml)	2 (7ml)	1 (30ml)	2 (30ml)
	G)	1 (8ml)	2 (8ml)	1 (30ml)	2 (30ml)

For Orders and Inquiries, please contact
Monobind Inc.
100 North Pointe Drive
Lake Forest, CA 92630 USA
Tel: +1 949.951.2665 Email: info@monobind.com
Fax: +1 949.951.3539 Web: www.monobind.com

IVD CE 2°C–8°C

EC REP CEpartner4U, Esdoornlaan 13, 3951 DB Maarn, The Netherlands www.cepartner4u.eu

СИСТЕМА СЕРТИФИКАЦИИ ГОСТ Р

ФЕДЕРАЛЬНОЕ АГЕНТСТВО ПО ТЕХНИЧЕСКОМУ РЕГУЛИРОВАНИЮ И МЕТРОЛОГИИ

Добровольная сертификация

СЕРТИФИКАТ СООТВЕТСТВИЯ

№ РОСС RU.ИМ02.Н18061

Срок действия с 24.06.2019г. по 24.06.2020г.

№ 0405450

ОРГАН ПО СЕРТИФИКАЦИИ № RA. RU.11ИМ02
МЕДИЦИНСКИХ ИЗДЕЛИЙ АНО «ВНИИИМТ»
129301, г. Москва, ул. Касаткина, д.3 тел. (495) 683-97-92, факс (499)187-89-54,
e-mail: im02@bk.ru

ПРОДУКЦИЯ Индикаторы паровой стерилизации химические одноразовые «ИНТЕСТ-П-«ВИНАР» по ТУ 9398-041-11764404-2003
Серийный выпуск.

код ОК
034-2014 (КПЕС 2008)
32.50.50.190

СООТВЕТСТВУЕТ ТРЕБОВАНИЯМ НОРМАТИВНЫХ ДОКУМЕНТОВ

код ТН ВЭД
3822 00 000 0

ГОСТ ISO 11140-1-2011 (класс 4),
ГОСТ Р 50444-92 (разделы 3,5,8)

ИЗГОТОВИТЕЛЬ Общество с ограниченной ответственностью «Научно-производственная фирма «ВИНАР» (ООО «НПФ «ВИНАР»), Россия, 105094, г. Москва, Госпитальный вал, д.5, стр.7А, пом.VIII ИНН 5023001024
Место производства-141009, Московская обл., г.Мытищи, ул.Колонцова,д.17/2

СЕРТИФИКАТ ВЫДАН Общество с ограниченной ответственностью «Научно-производственная фирма «ВИНАР» (ООО «НПФ «ВИНАР»), Россия, 105094, г. Москва, Госпитальный вал, д.5, стр.7А, пом.VIII
тел./факс (495) 988-76-67

НА ОСНОВАНИИ протокола испытаний № 16-853 от 20.06.2016г. ИЦ МИ АНО «ВНИИИМТ» (№ RA.RU.21ИМ04).

Регистрационные удостоверения № РЗН 2013/39 от 08.02.2013г. Федеральной службы по надзору в сфере здравоохранения (РОСЗДРАВНАДЗОР)

ДОПОЛНИТЕЛЬНАЯ ИНФОРМАЦИЯ Маркирование продукции производится знаком соответствия Системы сертификации ГОСТ Р при добровольной сертификации продукции

ОРГАН ПО СЕРТИФИКАЦИИ МЕДИЦИНСКИХ ИЗДЕЛИЙ Для сертификатов и деклараций RA.RU.11ИМ02 АНО "ВНИИИМТ"

Руководитель органа _____ (подпись) Е. И. Полянская (инициалы, фамилия)

Эксперт _____ (подпись) В.В. Русова (инициалы, фамилия)

Сертификат не применяется при обязательной сертификации

АО «ОПЦИОН», Москва, 2013, «Б» - лицензия №05-05-09/003 ФНС РФ, тел. (495) 726-4742, www.opcion.ru

EC Certificate

Directive 98/79/EC Annex IV, excluding Sections 4 and 6
Full Quality Assurance System
In Vitro Diagnostic Medical Devices

Registration No.: HL 60119814 0001

Report No.: 21265422 001

Manufacturer: Macherey-Nagel GmbH & Co. KG
Neumann-Neander-Str. 6-8
52355 Düren
Deutschland

Products: Products for self-testing

(see attachment for products and sites included)

Replaces Certificate, Registration No.: HL 60076687 0001

Expiry Date: 2022-05-28

The Notified Body hereby declares that the requirements of Annex IV, excluding section 4 and 6 of the directive 98/79/EC have been met for the listed products. The above named manufacturer has established and applies a quality assurance system, which is subject to periodic surveillance, defined by Annex IV, section 5 of the aforementioned directive. For placing on the market of List A devices covered by this certificate an EC design-examination certificate according to Annex IV, section 4 and a verification of manufactured products according to section 6 is required.

Effective Date: 2017-05-29

Date: 2017-05-29

Notified Body

Dipl.-Ing. Sven Hoffmann

TÜV Rheinland LGA Products GmbH - Tillystraße 2 - 90431 Nürnberg

TÜV Rheinland LGA Products GmbH is a Notified Body according to Directive 98/79/EC concerning in vitro diagnostic medical devices with the identification number 0197.

TÜV Rheinland
LGA Products GmbH
Tillystraße 2, 90431 Nürnberg

Attachment to
Certificate
Registration No.: HL 60119814 0001
Report No.: 21265422 001

Manufacturer: Macherey-Nagel GmbH & Co. KG
Neumann-Neander-Str. 6-8
52355 Düren
Deutschland

Products for self-testing:
- Single and multi-parameter disposable test strips for urine analysis
- indicator test strips and papers for measurement of pH in urine

Additional site for warehousing and logistics:

Bahnstr. 120
52355 Düren, Germany

Notified Body

Date: 2017-05-29

Dipl.-Ing. Sven Hoffmann